Merck’s Covid Treatment Pill Wins Blessing of F.D.A. Panel November 30, 2021 Auto Bot antibodies, Clinical Trials, Coronavirus (2019-nCoV), Coronavirus Delta Variant, Coronavirus Omicron Variant, Food and Drug Administration, Merck & Company Inc, Molnupiravir (Drug) 0 The treatment, known as molnupiravir, could be authorized in the United States within days, and available within weeks, if the F.D.A. follows the committee’s recommendation.